idecabtagene vicleucel
2seventy bio,bms
rwe for ide-cel. crs and icans maybe related to tumor burden and ps. prior bcma somewhat negative, lower pfs &amp; os. also hr mm. but results are actually good. despite selection for trials. #ims2022 #mmsm 
Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement